Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database

[1]  Sun Young Min,et al.  Basic Facts of Breast Cancer in Korea in 2014: The 10-Year Overall Survival Progress , 2017, Journal of breast cancer.

[2]  Chuang Chen,et al.  Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes , 2016, Oncotarget.

[3]  E. Hwang,et al.  Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. , 2015, Journal of the National Cancer Institute.

[4]  Ping Sun,et al.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. , 2015, JAMA oncology.

[5]  J. Bruce,et al.  Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. , 2014, Breast.

[6]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[7]  M. Kerin,et al.  Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype , 2012, Breast Cancer Research and Treatment.

[8]  T. Julian,et al.  Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Keda Yu,et al.  Different Distribution of Breast Cancer Subtypes in Breast Ductal Carcinoma in situ (DCIS), DCIS with Microinvasion, and DCIS with Invasion Component , 2011, Annals of Surgical Oncology.

[10]  T. Julian,et al.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. , 2011, Journal of the National Cancer Institute.

[11]  J. Cuzick,et al.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial , 2010, The Lancet. Oncology.

[12]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Han,et al.  Comparable survival between pN0 breast cancer patients undergoing sentinel node biopsy and extensive axillary dissection: a report from the Korean Breast Cancer Society. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Han,et al.  Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Barbara L. Smith,et al.  Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Han,et al.  Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Pedotti,et al.  Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ , 2003, The Lancet.

[18]  K. Kerlikowske,et al.  Detection of ductal carcinoma in situ in women undergoing screening mammography. , 2002, Journal of the National Cancer Institute.

[19]  N. Wolmark,et al.  Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. , 2001, Seminars in oncology.

[20]  J Costantino,et al.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17 , 1999, Cancer.

[21]  J. Costantino,et al.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.